The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. METHODS: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. RESULTS: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22%, P=0.01). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). CONCLUSIONS: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in a prospective RCT, the addition of DFX to patients with proven or probable mucormycosis treated with antifungal liposomal amphotericin B increased the mortality (Spellberg et al., 2011).”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a recent clinical trial in patients after allogenic bone marrow transplantation who received the iron chelator desferrasirox in an attempt to improve the control of mucormycosis, a devastating invasive fungal infection in severely immuno-compromised patients, failed to show a clinical benefit (Spellberg et al., 2012).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Spellberg et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
In the citing paper
“However, a small, multicenter clinical study using desferasirox as an adjunct treatment in patients that develop mucormycosis after allogeneic bone marrow transplantation resulted in a rather unfavorable outcome, for reasons that are not clear [28].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/590004 · Cited by 826
Self-citationRecent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Self-citationIncreasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42164 · Cited by 324
Self-citationThe iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308
Self-citationTen Years' Experience in Zygomycosis at a Tertiary Care Centre in India
Chakrabarti, A., Das, A., Sharma, A., Panda, N., Das, S., Gupta, K. L., & Sakhuja, V. (2001) · Journal of Infection · doi:10.1053/jinf.2001.0831 · Cited by 249
Invasive zygomycosis in India: experience in a tertiary care hospital
Chakrabarti, A., Chatterjee, S. S., Das, A., Panda, N., Shivaprakash, M. R., Kaur, A., Varma, S. C., Singhi, S., Bhansali, A., & Sakhuja, V (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.076463 · Cited by 244
Singh, N., Aguado, J. M., Bonatti, H., Forrest, G., Gupta, K. L., Safdar, N., John, G. T., Pursell, K. J., Muñoz, P., Patel, R., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605445 · Cited by 233
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
Deferoxamine Therapy and Mucormycosis in Dialysis Patients: Report of an International Registry
Boelaert, J. R., Fenves, A. Z., & Coburn, J. W. (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80606-8 · Cited by 203
Boelaert, J. R., Van Cutsem, J., de Locht, M., Schneider, Y.-J., & Crichton, R. R. (1994) · Kidney International · doi:10.1038/ki.1994.89 · Cited by 168
Deferiprone iron chelation as a novel therapy for experimental mucormycosis
Ibrahim, A. S., Edwards, J. E., Fu, Y., & Spellberg, B. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl350 · Cited by 156
Self-citationDrosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis
Chamilos, G., Lewis, R. E., Hu, J., Xiao, L., Zal, T., Gilliet, M., Halder, G., & Kontoyiannis, D. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709578105 · Cited by 145
Self-citationDeferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis
Reed, C., Ibrahim, A., Edwards, J. E., Walot, I., & Spellberg, B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01065-06 · Cited by 136
Self-citationde Locht, M., Boelaert, J. R., & Schneider, Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90314-x · Cited by 124
Fatal Rhizopus Infections in Hemodialysis Patients Receiving Deferoxamine
WINDUS, D. W., STOKES, T. J., JULIAN, B. A., & FENVES, A. Z. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-678 · Cited by 110
Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis)
Cutsem, J. V., & Boelaert, J. R. (1989) · Kidney International · doi:10.1038/ki.1989.301 · Cited by 108
Ibrahim, A. S., Avanessian, V., Spellberg, B., & Edwards, J. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3343-3344.2003 · Cited by 97
Self-citationIron-chelating therapy with the new oral agent ICL670 (Exjade®)
Cappellini, M. D. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.09.002 · Cited by 96
Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Spellberg, B., Andes, D., Perez, M., Anglim, A., Bonilla, H., Mathisen, G. E., Walsh, T. J., & Ibrahim, A. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00361-09 · Cited by 93
Self-citationMucormycosis: association with deferoxamine therapy
Daly, A. L., Velazquez, L. A., Bradley, S., & Kauffman, C. A. (1989) · The American Journal of Medicine · doi:10.1016/s0002-9343(89)80836-8 · Cited by 92
Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases
Shoham, S., Magill, S. S., Merz, W. G., Gonzalez, C. E., Seibel, N. L., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., & Walsh, T. J. (2010) · Medical Mycology · doi:10.3109/13693780903311944 · Cited by 87
Effects of iron and desferrioxamine on Rhizopus infection
Abe, F., Inaba, H., Katoh, T., & Hotchi, M. (1990) · Mycopathologia · doi:10.1007/bf00446996 · Cited by 64
Intestinal Mucormycosis in Hemodialysis Patients Following Deferoxamine
Eiser, A. R., Slifkin, R. F., & Neff, M. S. (1987) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(87)80015-x · Cited by 38
The Effect of Deferoxamine on Different Zygomycetes
Boelaert, J. R., de Locht, M., & Schneider, Y. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.1.231 · Cited by 22
MUCORMYCOSIS IN DIABETIC KETOACIDOSIS: Role of Unbound Iron Binding Capacity of Transferrin
Abe, F., Shibuya, H., Tateyama, M., Ommura, Y., Azumi, N., & Kazuyuki, K. (1986) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1986.tb02822.x · Cited by 21
Llorente, A., Valero, I., García, E., Heras, I. D. L., Fraile, V., García, P., López, J., Salavert, M., & Bobillo, F. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2010.09.008 · Cited by 10
Cited by
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
“Thus, the study did not support the use of deferasirox as an adjuvant therapy in the treatment of mucormycosis, though patients under deferasirox treated arm had higher morbidity [90].”
ResultESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
“The ECIL-3 recommendations for the treatment of mucormycosis were mostly based on retrospective studies, registry data and small prospective non-controlled studies.(3,68-77) Few new data are available for the treatment of mucormycosis since the ECIL 4 and, therefore, the current recommendations are very similar (Table…”
MethodChallenges in the diagnosis and treatment of mucormycosis
Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., & Petrikkos, G. (2018) · Medical Mycology · doi:10.1093/mmy/myx101 · Cited by 568
Self-citationStone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“Early surgical intervention may be just as important as the use of an effective antifungal agent [93].”
Metadata
- Authors
- Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P.
- Affiliations
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- Duke Medical Center (US)
- University of Washington (US)
- Corresponding author
- Spellberg, Brad
- ORCID
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-20
- Volume
- 67
- Issue
- 3
- Pages
- 715-722
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC3383100
- OpenAlex
- W2116858171
- Cited by
- 308
- References
- 32
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 9 · 2023: 22 · 2022: 24 · 2021: 30 · 2020: 16 · 2019: 20 · 2018: 22 · 2017: 16 · 2016: 22 · 2015: 17 · 2014: 33 · 2013: 25 · 2012: 19
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Gilead Sciences
- Astellas Pharma
- National Institutes of Health (UL1TR000124)
- National Institute of Allergy and Infectious Diseases (R01AI081719, R01AI063503)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Mycology
- Keywords
- mucormycosis, deferasirox, liposomal amphotericin B, iron chelation, adjunctive therapy, mortality, treatment safety
- MeSH terms
- Deferasirox, Adult, Aged, Amphotericin B, Animals, Antifungal Agents, Benzoates, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Iron Chelating Agents, Male, Middle Aged, Mucormycosis, Placebos, Triazoles, Survival Analysis, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.